ABSTRACT
Real-world evidence has become the basis for approval and regulation of drugs and medical devices. Real-world study has played a more and more important role with the continuous updating and iteration of medical technologies. The diseases and their underlying mechanisms in the neonatal period, the early stage of life, are significantly different from other stages of life and early high-quality clinical management has a profound impact on the long-term outcomes. Therefore, it is necessary to provide robust evidence for clinical diagnosis and treatment through real-world study. This paper explores the access to high-quality medical care in the neonatal period based on the application, challenges, and thinking of the China Neonatal Network (CHNN) in the real world and the integration of the China Neonatal Genome Project and other multi-omics data.